The REMS program for the ERA drug class was established due to the risk of embryofetal toxicity seen from animal studies.

Both 6-month trials were randomized, controlled studies that evaluated PER-001 delivered in a slow-release, dissolvable ...

Dublin, March 04, 2025 (GLOBE NEWSWIRE) -- The "Endothelin Receptor Antagonist - Pipeline Insight, 2025" clinical trials has been added to ResearchAndMarkets.com's offering. This report provides ...

Are selective endothelin-receptor antagonists really an important new advance for treating patients with treatment-resistant hypertension? The evidence from a recent study leaves us with some ...

In this Healio Video Perspective from Clinical Trials at the Summit, Arshad M. Khanani, MD, MA, FASRS, highlights first-time ...

The researchers examined the effect of three antioxidants—luteolin, hesperetin, and diosmetin—on mice specially bred to gray ...

Endothelin (ET) is a recently discovered 21-amino acid peptide that has potent physiologic and pathophysiologic effects that appear to be involved in the development of heart failure.

CHICAGO, IL—Use of an investigational endothelin receptor antagonist in patients with resistant hypertension has a significant impact on both automated office and 24-ambulatory blood pressure when ...

The team found that JMJD3 absence decreased the production of endothelin receptor-B while increasing endothelin receptor-A levels, which limited vessel dilation and raised blood pressure.

Since the endothelin pathway was not yet tackled in these patients, we selected aprocitentan, an endothelin receptor antagonist with the ideal properties for use in this condition.

CHICAGO — Aprocitentan, a dual endothelin antagonist, was superior to placebo for BP lowering and was well tolerated in patients with resistant hypertension, according to results of the ...